Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05659888
Other study ID # DCV-2017-11843
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date July 25, 2022
Est. completion date December 31, 2023

Study information

Verified date December 2022
Source Clinical Operations WCN B.V.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Guideline recommended evidence-based clinical care correlates with improved patient outcomes. In real life care, however, adherence to guideline recommendations remains suboptimal. In real life, patients may receive suboptimal treatment and as a result treatment targets are not always met. To support and improve secondary prevention for cardiovascular disease, PENELOPE and PENELOPE-CTRL are designed to support guideline implementation on lipid management and provide valuable feedback to care-givers on real world data.


Description:

The recent PENELOPE study was designed to determine the effect of a protocolized, Dutch-, and ESC- guideline based strategy of stepwise intensified lipid management in patients at very high risk for ACS. In PENELOPE 22 Dutch non-academic hospitals, members of the WCN investigator network, implemented a protocol guided guideline approach in a consecutive cohort of very high-risk patients admitted for ACS over the period 01-01-2019 to 31-08-2020. Lipid values and medication strategy are collected at baseline (index ACS), and after three months and one year post ACS, in order to establish the percentage of patients on target (LDL). The current PENELOPE-CTRL study on the other hand, is designed to serve as a contemporary control cohort for PENELOPE. PENELOPE-CTRL is a retrospective observational study, creating a contemporary snapshot of real-life lipid management for secondary prevention in very high-risk patients. PENELOPE-CTRL will collect data in similar hospitals who did not participate in the PENELOPE trial. To allow comparison of these two strategies, protocol guided versus real life implementation of the cholesterol treatment guidelines, both cohorts include similar patients, and similar data will be collected (e.g., lipid lowering drugs, lipid panels) . Analysis will be done at similar time points. Comparing the real-life data from PENELOPE-CTRL with the data from the PENELOPE study will quantify the effect of a strategy of protocolized guideline-based lipid management with regards to the incidence of target LDL-C levels in very high-risk patients, 3 months and one year after hospitalisation with a myocardial infarction.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 700
Est. completion date December 31, 2023
Est. primary completion date January 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Age >18 and =70 years - Alive at hospital discharge after admission for (N)STEMI between 1-1-2019 and 31-08-2020 - Planned for follow-up at a participating PENELOPE CTRL site - History of T2DM and/or history of ASCVD defined as either one of: - cerebrovascular disease/ event: transient ischemic attack, cerebral infarction, amaurosis fugax, retinal infarction - Coronary artery disease/ event: unstable angina pectoris, MI, ACS, coronary revascularization (coronary angioplasty or surgical procedure for coronary bypass) - Peripheral artery disease (symptomatic and documented obstruction of a distal extremity artery or surgical intervention (percutaneous transluminal angioplasty, bypass or amputation) Exclusion Criteria: - Pregnant and lactating women - Participation in lipid modifying drug trials up to two years after index cardiovascular event

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Netherlands NoordWest Hospital (NWZ) Alkmaar
Netherlands Reinier de Graaf Hospital Delft
Netherlands Haaglanden Hospital Den Haag
Netherlands Haga Hospital Den Haag
Netherlands Deventer Hospital Deventer
Netherlands Treant Hospital Emmen
Netherlands Saxenburg Medisch Centrum Hardenberg
Netherlands Elkerliek Hospital Helmond
Netherlands Alrijne Hospital Leiden
Netherlands Isala Hospital Meppel
Netherlands Canisius Wilhemina Hospital (CWZ) Nijmegen
Netherlands Diakonessenhuis Utrecht Utrecht
Netherlands Maxima Medisch Centrum Veldhoven

Sponsors (2)

Lead Sponsor Collaborator
Clinical Operations WCN B.V. Sanofi

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients reaching the LDL-C target level (= 1.8 mmol/L) reaching LDL-C target level (= 1.8 mmol/L) 3 months after admission for a type I (N)STEMI, compared to the designated PENELOPE cohort 3 months
Secondary Incidence of LDL-C target level (= 1.8 mmol/L) Incidence of LDL-C (= 1.8 mmol/L) at baseline (admission for a type I (N)STEMI), 3 months and 1 year after baseline, compared to the designated PENELOPE cohort. 1 year
Secondary Incidence of LDL-C target level (= 1.4 mmol/L) Incidence of LDL-C (= 1.4 mmol/L) at baseline (admission for a type I (N)STEMI), 3 months and 1 year after baseline, compared to the designated PENELOPE cohort. 1 year
Secondary incidence of achieving 50% LDL-C reduction Incidence of achieving 50% LDL-C reduction compared to baseline, after 3 months and 1 year, also adjusted to the start date of the related drug regimen. 1 year
Secondary LLT compared to PENELOPE cohort Lipid lowering therapy at baseline, after 3 months and 1 year, compared to the designated PENELOPE cohort. 1 year
Secondary LDL-C level 3 months after adjustment LDL-C level at 3 months, also adjusted to the start date of the related drug regimen. 3 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
Completed NCT01325116 - Delayed Educational Reminders in Acute Myocardial Infarction (MI) N/A
Completed NCT01452139 - Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI) Phase 2/Phase 3
Completed NCT01625104 - Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI N/A
Completed NCT04023266 - A Pilot Randomized Controlled Trial of Intravenous N-acetyl Cysteine in STEMI Phase 2
Completed NCT02170103 - Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial N/A
Completed NCT03103620 - Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
Not yet recruiting NCT05975567 - Deploying Novel Imaging Modalities Towards a Three-dimensional (3D) CARDIOvascular PATHology
Enrolling by invitation NCT03328156 - Erectile Dysfunction After Percutaneous Coronary Intervention Versus the Thrombolytic Therapy in Acute ST Elevation Myocardial Infarction N/A
Completed NCT04017169 - No Reflow Phenomenon Incidence and Predictors
Completed NCT03470441 - A Study of Acute Myocardial Infarction Using FDY-5301 Phase 2
Active, not recruiting NCT01433627 - Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX Phase 3
Completed NCT01197742 - Sweetheart-Register: Risk Management of Diabetics With Acute Myocardial Infarction N/A
Terminated NCT03439150 - Resistance STEMI Study N/A
Recruiting NCT03998319 - A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients. Phase 3
Not yet recruiting NCT05974930 - Intravascular ULTRAsound-Guided PCI in Patients With ST-Elevation Myocardial Infarction
Active, not recruiting NCT03102723 - Platelet Inhibition to Target Reperfusion Injury Phase 2
Completed NCT03930589 - Remote Ischemic Conditioning in STEMI to Decrease Infarct Size N/A
Not yet recruiting NCT04912167 - The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction Phase 3
Completed NCT02942550 - Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients Phase 4